Search results for "Positron-emission tomography"

showing 10 items of 228 documents

Simulated one-pass list-mode: an approach to on-the-fly system matrix calculation.

2013

In the development of prototype systems for positron emission tomography a valid and robust image reconstruction algorithm is required. However, prototypes often employ novel detector and system geometries which may change rapidly under optimization. In addition, developing systems generally produce highly granular, or possibly continuous detection domains which require some level of on-the-fly calculation for retention of measurement precision. In this investigation a new method of on-the-fly system matrix calculation is proposed that provides advantages in application to such list-mode systems in terms of flexibility in system modeling. The new method is easily adaptable to complicated sy…

Mathematical optimizationRadiological and Ultrasound Technology010308 nuclear & particles physicsRandom number generationDetectorProcess (computing)Iterative reconstructionMaximizationSystems modelingModels Theoretical01 natural sciences030218 nuclear medicine & medical imaging03 medical and health sciencesNoise0302 clinical medicinePositron-Emission Tomography0103 physical sciencesImage Processing Computer-AssistedRadiology Nuclear Medicine and imagingAlgorithmImage resolutionMathematicsPhysics in medicine and biology
researchProduct

Measurement of cerebral ABCC1 transport activity in wild-type and APP/PS1-21 mice with positron emission tomography

2020

Previous data suggest a possible link between multidrug resistance-associated protein 1 (ABCC1) and brain clearance of beta-amyloid (Aβ). We used PET with 6-bromo-7-[11C]methylpurine ([11C]BMP) to measure cerebral ABCC1 transport activity in a beta-amyloidosis mouse model (APP/PS1-21) and in wild-type mice aged 50 and 170 days, without and with pretreatment with the ABCC1 inhibitor MK571. One hundred seventy days-old-animals additionally underwent [11C]PiB PET scans to measure Aβ load. While baseline [11C]BMP PET scans detected no differences in the elimination slope of radioactivity washout from the brain (kelim) between APP/PS1-21 and wild-type mice of both age groups, PET scans after MK…

Mice TransgenicNeuroimaging03 medical and health sciencesAmyloid beta-Protein PrecursorMice0302 clinical medicineMethylpurineAlzheimer Diseasemental disordersmedicinePresenilin-1Animals030304 developmental biology0303 health sciencesmedicine.diagnostic_testbiologyTransport activityChemistryWild typeOriginal ArticlesMolecular biologyMice Inbred C57BLDisease Models AnimalNeurologyPositron emission tomographyPositron-Emission TomographyABCC1biology.proteinFemaleNeurology (clinical)Multidrug Resistance-Associated Protein 1Multidrug Resistance-Associated ProteinsRadiopharmaceuticalsCardiology and Cardiovascular Medicine030217 neurology & neurosurgeryJournal of Cerebral Blood Flow & Metabolism
researchProduct

Past, present and future of 68Ge/68Ga generators.

2013

(68)Ga represents one of the very early radionuclides applied to positron emission tomography (PET) imaging at a time when even the wording PET itself was not established. Today it faces a renaissance in terms of new (68)Ge/(68)Ga radionuclide generators, sophisticated (68)Ga radiopharmaceuticals, and state-of-the-art clincial diagnoses via positron emission tomography/computed tomography (PET/CT). Thanks to the pioneering achievement of radiochemists in Obninsk, Russia, a new type of (68)Ge/(68)Ga generators became commercially available in the first years of the 21st century. Generator eluates based on hydrochloric acid provided "cationic" (68)Ga instead of "inert" (68)Ga-complexes, openi…

Multimodal imagingmedicine.medical_specialtyRadiationmedicine.diagnostic_testRadionuclide GeneratorsThe RenaissanceComputed tomographyGallium RadioisotopesEngineering physicsMultimodal ImagingX ray computedPositron emission tomographyPositron-Emission TomographymedicineMedical physicsRadionuclide GeneratorRadiopharmaceuticalsTomography X-Ray ComputedApplied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
researchProduct

Design of Bimodal Ligands of Neurotensin Receptor 1 for Positron Emission Tomography Imaging and Fluorescence-Guided Surgery of Pancreatic Cancer

2020

International audience; Neurotensin receptor 1 (NTSR1) is overexpressed in most human pancreatic ductal adenocarcinomas. It makes it an attractive target for the development of pancreatic cancer imaging agents. In this study, we sought to develop a bimodal PET-fluorescent imaging agent capable of specifically targeting these receptors. Starting from the structure of a known NTSR1 agonist, a series of tracers was synthesized, radiometalated with gallium-68 and evaluated in vitro and in vivo, in mice bearing an AsPC-1 xenograft. PET imaging allowed us to identify the compound [ 68 Ga]Ga-NODAGA-Lys(Cy5**)-AEEAc-[Me-Arg 8 , Tle 12 ]-NT(7-13) as the one with the most promising biodistribution pr…

Neurotensin receptor 1positron emission tomographydual-modality[SDV]Life Sciences [q-bio]Gallium RadioisotopesAcetatesLigands01 natural sciencesHeterocyclic Compounds 1-RingMice03 medical and health sciencesgallium-68Cell Line TumorPancreatic cancerDrug DiscoverymedicineAnimalsHumansReceptors Neurotensin[CHIM]Chemical SciencesPancreatic carcinomaPancreasNeurotensinFluorescent Dyes030304 developmental biology0303 health sciencesmedicine.diagnostic_testChemistryOptical Imagingmedicine.diseaseFluorescence0104 chemical sciencesPancreatic Neoplasms010404 medicinal & biomolecular chemistrySurgery Computer-AssistedPositron emission tomographyPositron-Emission TomographyCancer researchMolecular MedicineFemalefluorescence-guided surgery
researchProduct

Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.

2014

Objective To analyze the feasibility of laparoscopic/robotic secondary cytoreductive surgery and hyperthermic intraperitoneal intra-operative chemotherapy (SCS + HIPEC) in a retrospective series of isolated platinum sensitive recurrent ovarian cancer. Methods We retrospectively evaluated a consecutive series of ovarian cancer patients with isolated platinum sensitive relapse. Isolated relapse was defined as the presence of a single nodule, in a single anatomic site. In all cases the presence of isolated relapse was assessed at pre-operative FDG-PET/CT scan, and confirmed with staging laparoscopy performed immediately before SCS + HIPEC. Results 84 women with platinum sensitive relapse recei…

OVARIAN CANEROrganoplatinum Compoundsmedicine.medical_treatmentdrug therapy/pathology/surgery/therapyCarcinoma Ovarian EpithelialMultimodal ImagingCohort StudiesObstetrics and gynaecologyNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsInfusions ParenteralNeoplasms Glandular and EpithelialLaparoscopyadministration /&/ dosageTomographyRandomized Controlled Trials as TopicOvarian Neoplasmsmedicine.diagnostic_testObstetrics and GynecologyGlandular and EpithelialMiddle AgedDebulkingCombined Modality TherapyIsolated platinum sensitive relapseX-Ray ComputedOxaliplatinPhase III as TopicOncologyFemalediagnostic usemedicine.drugmedicine.medical_specialtyInfusionsAged Antineoplastic Combined Chemotherapy Protocols; administration /&/ dosage Cisplatin; administration /&/ dosage Clinical Trials; Phase II as Topic Clinical Trials; Phase III as Topic Cohort Studies Combined Modality Therapy Female Fluorodeoxyglucose F18; diagnostic use Humans Hyperthermia; Induced; methods Infusions; Parenteral Middle Aged Minimally Invasive Surgical Procedures Multimodal Imaging Neoplasms; Glandular and Epithelial; drug therapy/pathology/surgery/therapy Organoplatinum Compounds; administration /&/ dosage Ovarian Neoplasms; drug therapy/pathology/surgery/therapy Positron-Emission Tomography Radiopharmaceuticals; diagnostic use Randomized Controlled Trials as Topic Retrospective Studies Tomography; X-Ray Computed ocal; pathologyocalmethodsClinical Trials Phase II as TopicMinimally invasive surgeryOvarian cancerFluorodeoxyglucose F18ParenteralmedicineHumansMinimally Invasive Surgical ProceduresClinical TrialsHyperthermiaAgedRetrospective StudiesCisplatinChemotherapySeries (stratigraphy)HIPECbusiness.industryPhase II as TopicInducedHyperthermia Inducedmedicine.diseaseOxaliplatinSurgeryRoboticSettore MED/40 - GINECOLOGIA E OSTETRICIAClinical Trials Phase III as TopicPositron-Emission TomographyLaparoscopypathologyNeoplasm Recurrence LocalCisplatinRadiopharmaceuticalsbusinessOvarian cancerTomography X-Ray Computed
researchProduct

Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

2015

Abstract Purpose: To investigate the value of the metabolic tumor response assessed with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), compared with clinicobiologic markers to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in women with triple-negative breast cancer (TNBC). Experimental Design: Fifty consecutive women with TNBC and an indication for NAC were prospectively included. Different pretreatment clinical, biologic, and pathologic biomarkers, including SBR grade, the Ki-67 proliferation index, androgen receptor expression, EGF receptor (EGFR), and cytokeratin 5/6 staining, were assessed. Tumor glucose metabolism at baseline and its chan…

OncologyAdultCancer Researchmedicine.medical_specialtyPathologyProliferation indexmedicine.medical_treatmentBiopsyTriple Negative Breast NeoplasmsBreast cancerFluorodeoxyglucose F18Internal medicineBiopsyAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansEpidermal growth factor receptorTriple-negative breast cancerNeoadjuvant therapyAgedNeoplasm StagingChemotherapymedicine.diagnostic_testbiologybusiness.industryOdds ratioMiddle Agedmedicine.diseasePrognosisCombined Modality TherapyNeoadjuvant TherapyTumor BurdenGlucoseTreatment OutcomeOncologyROC CurveLymphatic MetastasisPositron-Emission Tomographybiology.proteinFemaleNeoplasm GradingbusinessTomography X-Ray ComputedBiomarkersClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Role of Positron Emission Tomography for the Monitoring of Response to Therapy in Breast Cancer

2015

Abstract This review considers the potential utility of positron emission tomography (PET) tracers in the setting of response monitoring in breast cancer, with a special emphasis on glucose metabolic changes assessed with 18F-fluorodeoxyglucose (FDG). In the neoadjuvant setting of breast cancer, the metabolic response can predict the final complete pathologic response after the first cycles of chemotherapy. Because tumor metabolic behavior highly depends on cancer subtype, studies are ongoing to define the optimal metabolic criteria of tumor response in each subtype. The recent multicentric randomized AVATAXHER trial has suggested, in the human epidermal growth factor 2-positive subtype, a …

OncologyCancer Researchmedicine.medical_specialtyPathologyResponse to therapyReceptor ErbB-2medicine.medical_treatmentBreast Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineHealth outcomesTumor response030218 nuclear medicine & medical imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciences0302 clinical medicineBreast cancerFluorodeoxyglucose F18Internal medicineBreast CancerHumansMedicineskin and connective tissue diseasesComputingMilieux_MISCELLANEOUSChemotherapymedicine.diagnostic_testbusiness.industryTumor biologyCancerPrognosismedicine.disease3. Good healthRadiographyOncologyPositron emission tomographyPositron-Emission Tomography030220 oncology & carcinogenesisFemalebusiness
researchProduct

Genotyping analysis and 18FDG uptake in breast cancer patients: a preliminary research

2013

Background: Diagnostic imaging plays a relevant role in the care of patients with breast cancer (BC). Positron Emission Tomography (PET) with 18F-fluoro-2-deoxy-D-glucose (FDG) has been widely proven to be a clinical tool suitable for BC detection and staging in which the glucose analog supplies metabolic information about the tumor. A limited number of studies, sometimes controversial, describe possible associations between FDG uptake and single nucleotide polymorphisms (SNPs). For this reason this field has to be explored and clarified. We investigated the association of SNPs in GLUT1, HIF-1a, EPAS1, APEX1, VEGFA and MTHFR genes with the FDG uptake in BC. Methods: In 26 caucasian individu…

OncologyCancer Researchmedicine.medical_specialtyPathologydbSNPGenotypePET-CTSingle-nucleotide polymorphismStandardized uptake valueBreast NeoplasmsGene mutationMultimodal ImagingPolymorphism Single NucleotideBreast cancerBreast cancerFluorodeoxyglucose F18Internal medicinemedicineHumansPET-CTSUVpvcbiologybusiness.industryResearchGlucose analogSUVmaxSingle nucleotide polymorphismsmedicine.diseaseSingle nucleotide polymorphismBreast cancer Single nucleotide polymorphisms PET-CT SUVmax SUVpvcOncologyMethylenetetrahydrofolate reductasePositron-Emission Tomographybiology.proteinFemaleRadiopharmaceuticalsbusinessTomography X-Ray Computed
researchProduct

Positron emission tomography and neoadjuvant therapy of breast cancer

2011

The increasing use of neoadjuvant therapy for breast cancer has led to the development of early surrogate markers of response. Positron emission tomography (PET) allows noninvasive study of fundamental biologic processes in the tumor; furthermore, PET provides various markers to assess tumor response early in the course of therapy. Numerous studies have shown that changes in tumor glucose metabolism during therapy are significantly correlated with final response and patient outcome. Moreover, new PET tracers that are currently being developed or under evaluation, providing specific information on tumor characteristics or receptor expression, will assist the development of new targeted antic…

OncologyCancer Researchmedicine.medical_treatmentReceptor expressionTumor response030218 nuclear medicine & medical imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicineAntineoplastic Agent0302 clinical medicineMonoclonalPet tracerHumanizedAdjuvantNeoadjuvant therapyComputingMilieux_MISCELLANEOUSAntibodies Monoclonal Humanized; Antineoplastic Agents; Biomarkers Tumor; Breast Neoplasms; Chemotherapy Adjuvant; Female; Fluorodeoxyglucose F18; Humans; Radiopharmaceuticals; Trastuzumab; Neoadjuvant Therapy; Positron-Emission Tomography; Cancer Research; Oncology; Medicine (all)Tumormedicine.diagnostic_testMedicine (all)General MedicineNeoadjuvant Therapy3. Good healthOncologyChemotherapy AdjuvantPositron emission tomography030220 oncology & carcinogenesisRadiopharmaceuticalFemaleBreast NeoplasmHumanmedicine.medical_specialtyAntineoplastic AgentsBreast Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineAntibodies Monoclonal HumanizedAntibodies[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciencesBreast cancerFluorodeoxyglucose F18Internal medicineBiomarkers TumormedicineChemotherapyHumansbusiness.industryTrastuzumabmedicine.diseasePositron-Emission TomographyRadiopharmaceuticalsbusinessBiomarkers
researchProduct

[11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile a…

2010

[11C]choline positron emission tomograhy can be useful to detect metastatic disease and to localize isolated lymph node relapse after primary treatment in case of prostate-specific antigen failure. In case of lymph node failure in prostate cancer patients, surgery or radiotherapy can be proposed with a curative intent. Some reports have suggested that radiotherapy could have a role in local control of oligometastatic lymph node disease. This is the first reported case of [11C]choline positron emission tomography-guided helical tomotherapy concomitant with estramustine for the treatment of pelvic-recurrent prostate cancer. At 24 months after the end of helical tomotherapy, prostate-specific…

OncologyMaleCancer Researchmedicine.medical_treatment[11C]choline-PET tomotherapy prostate relapse lymph node030218 nuclear medicine & medical imagingCholineProstate cancer0302 clinical medicineProstateCarbon RadioisotopesTomographyLymph nodeAdjuvantPelvic NeoplasmsrelapseprostateGeneral MedicineAlkylatingmedicine.anatomical_structureTreatment OutcomeLocalOncologyChemotherapy Adjuvant030220 oncology & carcinogenesis[11C]choline-PETEstramustineAged; Antineoplastic Agents Alkylating; Antineoplastic Agents Hormonal; Carbon Radioisotopes; Chemotherapy Adjuvant; Choline; Estramustine; Humans; Male; Neoplasm Recurrence Local; Pelvic Neoplasms; Prostatic Neoplasms; Radiotherapy Adjuvant; Treatment Outcome; Positron-Emission Tomography; Tomography Spiral ComputedEstramustinemedicine.drugmedicine.medical_specialtyAntineoplastic Agents HormonaltomotherapyAntineoplastic AgentsTomotherapy03 medical and health sciencesInternal medicinemedicinelymphChemotherapyHumansAntineoplastic Agents AlkylatingAgedChemotherapyHormonalRadiotherapybusiness.industryProstatic Neoplasmsmedicine.diseaseRadiation therapyNeoplasm RecurrenceConcomitantPositron-Emission TomographySpiral ComputedRadiotherapy AdjuvantNeoplasm Recurrence LocalbusinessTomography Spiral Computed
researchProduct